SynAct Pharma AB publishes Annual Report 2021

SynAct Pharma AB (“SynAct”) today announces that the Annual Report for 2021 is now available as a pdf on the group’s web page, www.synactpharma.com. A pdf version is also attached to this press release.

The information was submitted, through the agency of the contact person below, for publication at 09:00 a.m. CEST on April 29, 2022.

For further information about SynAct Pharma AB, please contact:  

Jeppe Øvlesen                                    
CEO, SynAct Pharma AB                    
Phone: +45 28 44 75 67                       
Mail: joo@synactpharma.com           

Patrik Renblad
CFO, SynAct Pharma AB
Phone: +46 707 47 97 68
Mail: par@synactpharma.com

About SynAct Pharma AB 

SynAct Pharma AB conducts research and development in inflammatory diseases. The company has a platform technology based on a new class of drug candidates aimed at acute deterioration in chronic inflammatory diseases with the primary purpose of stimulating natural healing mechanisms. For more information: www.synactpharma.com.